NORCROSS, Ga., June 24,
2024 /PRNewswire/ -- Hi-Tech Pharmaceuticals, Inc., a
specialty pharmaceutical and dietary supplement company, today
announced plans to launch a highly purified NMN+NR product
following the recent successful completion of a pilot scale launch
last year. β-Nicotinamide mononucleotide (NMN) is a derivative of
the B-vitamin niacin, which is believed to significantly improve
health and wellness.
NMN is a natural compound found in the human body and is
constantly being metabolized. It is also found in trace amounts in
certain foods. NMN serves as a precursor to NAD+, which is a
coenzyme found in all living cells, and is required for the body's
core biological processes, including the human body's energy
production, metabolism, and gene expression.
Nicotinamide Riboside (NR) is a naturally occurring molecule
found in all cells and a natural building block for NAD⁺
production. NR is designed to elevate NAD⁺ levels, maintain
cellular function, and enhance vitality and longevity.†
Together, this combination being designed by Hi-Tech
highlights that a multi-target strategy for NAD⁺ restoration such
as the use of a precursor in combination with inhibitors and/or
activators acting at other key points in the NAD⁺ network may be
the optimum approach to NAD⁺ restoration."
NMN+NR are precursors for NAD⁺, which plays a key role in many
vital processes, including:Energy production† DNA repair†
Regulation of genes† Cellular health and vitality† Immune function†
Regulation of the sleep-wake cycle†
Fortunately, NAD+ levels, which naturally decline with age, can
be replenished by with high quality NMN+NR supplements. Potential
benefits of restoring NAD+ levels include slowing the adverse
impacts of aging, support for an improved cardiovascular function,
and aiding wellness, a healthy weight management regimen and
endurance.
Cyclosome ® Delivery
Standard NMN and NR have limited absorption due to extensive
metabolism and low stability.† To address this issue, Hi-Tech uses
an advanced liposomal+cyclodextrin delivery system
(Cyclosome®) designed to improve the bioavailability,
created for better absorption, and a slower release into the
bloodstream.†
Jared Wheat, Hi-Tech's CEO,
commented, "We are gearing up to launch a
highly purified NMN+NR product given the success of our
recent pilot launch and high market demand. We expect to leverage
Hi-Tech Pharma's proven track record of providing superior
ingredients to ensure that customers are buying a high-quality,
pure NMN+NR supplement whenever they see our brand. We see NMN+NR
as a natural fit for our comprehensive healthcare category, which
is an ideal non-medicine therapy; and a new star for our
portfolio, which already boasts dozens of products with our
proprietary Cyclosome® delivery system, giving us added
revenue stability, visibility and the product pipeline needed to
support the Company's continued growth."
About Hi-Tech: Hi-Tech Pharmaceuticals is an enormously
successful company that creates, manufactures and sells
high-quality products. Hi-Tech has been able to increase its market
share in the United States through the acquisition
of sixteen acquisitions in recent years, which included the
manufacturing bases of Synergy Nutritional Industries in 2005
and Nittany Pharmaceuticals in Pennsylvania in 2012.Hi Tech
also acquired many large brands such as: APS Nutrition, ALR,
FormuTech Nutrition, Sports One, Innovative Laboratories, LG
Sciences, iForce Nutrition, Prime Nutrition, Top Secret Nutrition,
and EAS. Hi-Tech healthcare products based upon its proprietary
Cyclosome® Technology. Hi-Tech's recent strategy has been, and
according to its leaders will continue to be, growth through Merger
and Acquisition activity.
*These statements have not been evaluated by the Food and
Drug Administration. This product is not intended to diagnose,
treat, cure or prevent disease.
Media Contact:
Brandon
Schopp
770-797-9959
379478@email4pr.com
View original
content:https://www.prnewswire.com/news-releases/hi-tech-pharmaceuticals-to-launch-highly-purified-nmn-nr-product-302179662.html
SOURCE Hi-Tech Pharmaceuticals, Inc.